research Alopecia universalis successfully treated with tofacitinib
Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
Search
for
Sort by
Research
510-540 / 1000+ resultsresearch Vemurafenib-induced pityriasis amiantacea: a case report
Vemurafenib can cause scalp issues but can be managed without changing the dose.
research Alopecia Universalis Successfully Treated With Adalimumab
A woman with severe hair loss was successfully treated with the drug adalimumab.
research America - A Diversity of Life Styles.
The drug showed promise in treating renal cell carcinoma with manageable side effects.
research Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
research A Novel Topical Compound Gel Loading Minoxidil and Tofacitinib for Treatment of Alopecia Areata: Formulation, Characterization, and In Vitro/In Vivo Evaluation
The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
research Effects of mesenchymal stem cell therapy on alopecia areata in cellular and hair follicle organ culture models
Mesenchymal stem cell therapy may help treat alopecia areata by promoting hair growth and reducing inflammation.
research FORMULATION AND EVALUATION OF POLYHERBAL EMULGEL FOR RHEUMATOID ARTHRITIS
The polyherbal emulgel is a promising treatment for rheumatoid arthritis with effective and sustained results.
research Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
AZD6244 treatment causes skin aging effects by depleting skin stem cells.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Clinical Application of Development of Nonantibiotic Macrolides That Correct Inflammation-Driven Immune Dysfunction in Inflammatory Skin Diseases
Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
research 5PSQ-056 Experience with tofacinitib and baricitinib in rheumatoid arthritis
Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
research ANALYSIS OF EFFICACY OF USING PLATELET-RICH PLASMA AND BETAMETHAZONE IN THE TREEATMENT OF ALOPECIA AREATA
Combining betamethasone and PRP injections works best for treating alopecia areata.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy
Tempol is safe and may prevent hair loss from brain radiotherapy.
research Baricitinib as the first systemic treatment for severe alopecia areata
Baricitinib is effective as a treatment for severe hair loss.
research Repurposing of H1-receptor antagonists (levo)cetirizine, (des)loratadine, and fexofenadine as a case study for systematic analysis of trials on clinicaltrials.gov using semi-automated processes with custom-coded software
Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
research Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders
TYK2 inhibitors show promise for treating cancer and autoimmune disorders.
research Treatment of severe alopecia areata with oral tofacitinib: A case series
Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
research Alopecia areata flare patterns in children and young adults while on systemic tofacitinib
Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
research Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
JAK inhibitors show promise for treating alopecia areata but have serious side effects.
research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
research Tofacitinib therapy for the treatment of alopecia areata: Report of 11 patients
Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
research Effectiveness of oral tofacitinib treatment on patients with moderate‐to‐severe alopecia areata in Iran
Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
research Elevation of transaminases after MMP® session with methotrexate for alopecia areata treatment – how much do we know about the risks of systemic absorption of the technique?
research THERAPEUTIC CHALLENGES IN POLYAUTOIMMUNITY: ANIFROLUMAB FOR LUPUS ERYTHEMATODES IN OVERLAPPING AUTOIMMUNE SYNDROMES
Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.